Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 36, Issue 6, 1997, Pages 725-736

  Leonard, Henrietta L ^a,e   March, John ^b   Rickler, Kenneth C ^d   Allen, Albert John ^c  

^a BROWN UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d BROWN UNIVERSITY   (United States)

^e RHODE ISLAND HOSPITAL   (United States)

Author keywords

Fluoxetine; Fluvoxamine; Hepatic cytochrome P450; Paroxetine; Pediatric psychopharmacology; Selective serotonin reuptake inhibitors; Sertraline

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ASTEMIZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOMIPRAMINE; DESIPRAMINE; ERYTHROMYCIN; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; KETOCONAZOLE; LIDOCAINE; MIDAZOLAM; NEUROLEPTIC AGENT; NORFLUOXETINE; PAROXETINE; PERPHENAZINE; PIMOZIDE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TERFENADINE; THEOPHYLLINE; THIORIDAZINE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ANTICHOLINERGIC EFFECT; ARTICLE; CHILD PSYCHIATRY; DEPRESSION; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG OVERDOSE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; PRIORITY JOURNAL; SEIZURE; SEROTONIN SYNDROME; XEROSTOMIA;

EID: 0030950390     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-199706000-00008     Document Type: Article

References (109)

1. Achamallah NS (1992), Visual hallucinations after combining fluoxetine and dextromethorphan (letter). Am J Psychiatry 149:1406
2. Achamallah NS, Decker DH (1991), Mania induced by fluoxetine in an adolescent patient. Am J Psychiatry 148:1404
3. Ahmed I, Dagincourt PG, Miller LG, Shader RI (1993), Possible interaction between fluoxetine and pimozide causing sinus bradycardia. Can J Psychiatry 38:62-63
4. Altamura AC, Montgomery SA, Wernicke JF (1988), The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. Br J Psychiatry 53(suppl 3):109-112
5. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J (1996), Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 153:592-606
6. Apter A, Ratzoni G, King RA et al. (1994), Fluvoxamine open-label treatment of adolescent inpatients with OCD or depression. J Am Acad Child Adolesc Psychiatry 33:342-348
7. Barr LC, Goodman WK, Price L (1994), Physical symptoms associated with paroxetine discontinuation (letter). Am J Psychiatry 151:289
8. Bartels MG, Varley CK, Mitchell J, Stamm SJ (1991), Pediatric cardiovascular effects of imipramine and desipramine. J Am Acad Child Adolesc Psychiatry 30:100-103
9. Beasley CM, Dornseif BE, Bosomworth JC et al. (1991), Fluoxetine and suicide: a meta-analysis of controlled trials of treatment of depression. Br Med J 303:685-691
10. Birmaher B, Waterman GS, Ryan N et al. (1994), Fluoxetine for childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 33:993-999
11. Black DW Wesner R, Gabel J (1993), Abrupt discontinuation ot fluvoxamine in patients with panic disorder. J Clin Psychiatry 54:146-149
12. Bourin M, Couetoux D, Tertre A (1992), Pharmacokinetics of psychotropic drugs in children. Clin Neuropharmacol 15(suppl):114-225
13. Bradley SJ (1993), Fluoxetine and memory impairment. J Am Acad Child Adolesc Psychiatry 32:1078-1079
14. Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF (1993), Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 44:349-355
15. Brosen K, Skjelbo E, Rasmussen BB, Pousen HE, Loft S (1993), Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45:1211-1214
16. Budman CL, Sherlin M, Bruun RD (1995), Combined pharmacotherapy risk (letter). J Am Acad Child Adolesc Psychiatry 34:263-264
17. Burch KJ, Wells BG (1992), Fluoxetine/norfluoxetine concentrations in human milk. Pediatrics 89:676-677
18. Callahan AM Fava M, Rosenbaum JF (1993), Drug interactions in psychopharmacology. Pychiatr Clin North Am 16:647-671
19. Chambers CD, Johnson KA, Dick L, Felix R, Jones KL 1996, Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 335:1010-1015.
20. Choo V (1993), Paroxetine and extrapyramidal reactions. Lancet 341:624
21. Ciraulo DA, Shader RI (1990), Fluoxetine drug-drug interactions I: antidepressants and antipsychotics. J Clin Psychopharmaco 10:48-50
22. Coulter DM, Pillans PI (1995), Fluoxetine and extrapyramidal side effects. Am J Psychiatry 152:122-125
23. Coutts RT (1994), Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping. J Pychiatr Neurosci 19:30-44
24. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE (1992), The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 activity in human liver microsomes. Br J Clin Pharmacol 34:262-265
25. Cunningham M, Cunningham K, Lydiard RB (1990), Eye tics and subjective hearing impairment during fluoxetine therapy. Am J Psychiatry 147:947-948
26. DeVane C (1992), Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 53(suppl):13-20
27. Dilsaver SC, Greden JF (1984), Antidepressant withdrawal phenomena. Biol Psychiatry 19:237-252
28. Dorevitch A, Frankel Yehuda, Bar-Halperin A, Aronzon R, Zilberman L (1993), Fluvoxamine associated manic behavior: a case series. Ann Pharmacother 27:1455-1457
29. Dummit ES, Klein RG, Tancer NK, Asche B, Martin J (1996), Fluoxetine treatment of children with selective mutism: an open trial. J Am Acad Child Adolesc Psychiatry 35:615-621
30. Dunbar GC (1989), An interim overview of the safety and tolerability of paroxetine. Acta Psychiatr Scand 80(suppl 350):135-137
31. Dunner DL, Dunbar GC (1992), Optimal dose regimen for paroxetine. J Clin Psychiatry 53(suppl 2):21-26
32. Edleman RJ, Pfeffer CR, Ehlers KH (1994), Cardiac effects and fluoxetine (letter). J Am Acad Child Adolesc Psychiatry 33:591-592
33. Eisenhauer G, Jermain DM (1993), Fluoxetine and tics in an adolescent. Ann Pharmacother 27:725-726
34. Feder R (1991), Bradycardia and syncope induced by fluoxetine (letter). J Clin Psychiatry 52:139
35. Fennig S, Naisberg-Fenning S, Pato M, Weitzman A (1994), Emergence of symptoms of Tourette's syndrome during fluvoxamine treatment of obsessive-compulsive disorder. Br J Psychiatry 164:839-841
36. Fisch C (1985), Effect on fluoxetine on the electrocardiogram. J Clin Psychiatry 46:42-44
37. Fleishaker JC, Hulst KL (1994), A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 46:35-39
38. Gamier R, Azoyan P, Chataigner D, Taboulet P, Dellattre D, Efthymiou ML (1993), Acute fluvoxamine poisoning. J Int Med Res 21:197-208
39. Gatto G, Pikielny R, Micheli F (1994), Fluoxetine in Tourette's syndrome. Am J Psychiatry 151:946-947
40. Geller DA, Biederman J, Reed ED, Spencer T, Wilens TE (1995), Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 34:36-44
41. George MS, Trimble MR (1993), Dystonic reaction associated with fluvoxamine. J Clin Psychopharmacol 13:220-221
42. Ghaziuddin M (1994), Mania induced by sertraline in a prepubertal child (letter). Am J Psychiatry 151:944
43. Gillette DW, Tannery LP (1994), Beta blocker inhibits tricyclic metabolism. J Am Acad Child Adolesc Psychiatry 33:223-224
44. Heimann SW, March JS (1996), SSRJ-induced mania (letter). J Am Acad Child Adolesc Psychiatry 35:4-5
45. Hersh CB, Sokol, Pfeffer CR (1991), Transient psychosis with fluoxetine. J Am Acad Child Adolesc Psychiatry 30:851-852
46. Heym J, Koe BK (1988), Pharmacology of sertraline: a review. J Clin Psychiatry 49(suppl):40-45
47. Hoehn-Saric R, Harris GJ, Pearlson GD, Cox SC, Machlin ST, Camargo EF. (1991), A fluoxetine-induced frontal lobe syndrome in an obsessive compulsive patient. J Clin Psychiatry 52:131-133
48. Hoehn-Saric R, Lipsey JR, McLeod DR (1990), Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol 10:343-345
49. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena R (1992), Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 52:231-238
50. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR (1993), Terfenadine-ketoconazole interaction. JAMA 269:1513-1518
51. Horrigan JP, Barnhill LJ (1994), Paroxetine-pimozide drug interaction (letter). J Am Acad Child Adolesc Psychiatry 33:1060-1061
52. Hughes C, Preskorn SH (1989), Depressive syndromes in children and adolescents: diagnosis and treatment. Ann Clin Psychiatry 1:109-118
53. Hyman SE, Nestler EJ (1996), Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 153:151-162
54. Jafri AB, Greenberg WM (1991), Fluoxetine side effects. J Am Acad Child Adolesc Psychiatry 30:852
55. Jain U, Birmaher B, Garcia M, Al-Shabbout M, Ryan N (1993), Fluoxetine: a chart review of efficacy and adverse effects. J Child Adolesc Psychopharmacol 2:259-265
56. Jerome L (1991), Hypomania with fluoxetine. J Am Acad Child Adolesc Psychiatry 30:850-851
57. Joblin M (1994), Possible interaction of sertraline with carbamazepine (letter). NZ Med J 107:43
58. Jones-Fearing KB (1996), SSRI and EPS with fluoxetine (letter). J Am Acad Child Adolesc Psychiatry 35:1107-1108
59. Kalda R (1993), Media- or fluoxetine induced akathisia (letter)? Am J Psychiatry 150:531-532
60. Kat H (1996), More on SSRI-induced mania (letter). J Am Acad Child Adolesc Psychiatry 35:975-976
61. Ketai R (1993), Interaction between fluoxetine and neuroleptics (letter). Am J Psychiatry 150:836-837
62. King RA, Riddle MS, Chappell PB et al. (1991), Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 30:179-186
63. Koe BK (1990), Preclinical pharmacology of sertraline: a potent and specific inhibitor of serotonin reuptake. J Clin Psychiatry 51(suppl B):13-17
64. Lejoyeux M, Fineyre F, Ades J (1992), The serotonin syndrome. Am J Psychiatry 149:1410-1411
65. Leonard HL, Lenane MC, Swedo SE, Rettew DC, Rapport JL (1991), A double-blind comparison of clomipramine and desipramine treatment of severe onychophagia (nail-biting). Arch Gen Psychiatry 48:828-833
66. Leonard HL, Swedo SE, Rapoport JL et al. (1989), Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents: a double-blind crossover comparison. Arch Gen Psychiatry 46:1088-1092
67. Lydiard RB, Anton R, Cunningham T (1993), Interactions between sertraline and tricyclic antidepressants (letter). Am J Psychiatry 150:1125-1126
68. March JS, Moon RL, Johnston H (1990), Fluoxetine-TCA interaction (letter). J Am Acad Child Adolesc Psychiatry 29:986
69. Maskall DD, Lam RW (1993), Increased plasma concentration of imipramine following augmentation with fluvoxamine (letter). Am J Psychiatry 150:1566
70. Murdoch D, McTavish D (1992), Sertraline: a review of its pharmacodynamic and pharmacokinetic properties, therapeutic potential in depressive illness, and prospective role in the treatment of obsessive compulsive disorder. Drugs 44:604-624
71. Nemeroff CB (1993), Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in treatment of depression. J Clin Psychopharmacol 13(suppl):10-17
72. Nemeroff CB, DeVane CL, Pollock BG (1996), Newer antidepressants and the cytochrome P450 sysrem. Am J Psychiatry 153:311-320
73. Nicholson AN, Pascoe P (1988): Studies on the modulation of the sleep-wakefulness continuum in man by fluoxetine, a 5-HT uptake inhibitor. Neuropharmacology 27:597-602
74. Palmer KJ, Benfield P (1994), Fluvoxamine: an overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders. CNS Drugs 1:57-87
75. Paxton J, Dragunow M (1993), Pharmacology. In: Practitioner's Guide to Psychoactive Drugs for Children and Adolescents, Werry J, Aman M, eds. New York: Plenum, pp 34-46
76. Pearson HL (1990), Interaction of fluoxetine with carbamazepine (lerter). J Clin Psychiatry 51:126
77. Perucca E, Gattu G, Cipolla G et al. (1994), Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 56:471-476
78. Pohl R, Yeragani VK, Balon R, Lycaki H (1988), The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 49:100-104
79. Prasher VP (1993), Seizures associated with fluoxetine therapy. Seizure 2:315-317
80. Preskorn S (1993), Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 54(suppl):14-34
81. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S (1994), Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 14:90-98
82. Reynolds CF, Kupfer DJ (1987), Sleep research in affective illness: state of the art circa 1987. Sleep 10:199-215
83. Riddle MA, Brown N, Dzubinski D, Jetmalani AN, Law Y, Woolston JL (1989), Fluoxetine overdose in an adolescent. J Am Acad Child Adolesc Psychiatry 23:587-588
84. Riddle MA, Claghorn J, Gaffney G et al. (1996), Fluvoxamine for children and adolescents with OCD: a controlled multicenter trial. Presented at the 43rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Philadelphia, October 25
85. Riddle MA, King RA, Hardin MT et al. (1991), Behavioral side effects of fluorine in children and adolescents. J Child Adolesc Psychopharmacol 1:193-198
86. Riddle MA, Scahill L, King RA et al. (1992) Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 31:1062-1069
87. Saletu B, Frey R, Krupka M, Anderer P, Grunberger J, See WR (1991), Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 14:439-447
88. Shader RI, Greenblatt DJ, von Moltke LL (1994), Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol 14:375-376
89. Shihabuddin L, Rapport D (1994), Sertraline and extrapyramidal side effects. Am J Psychiatry 151:288-289
90. Shimoda, Minowada T, Noguchi T, Takahashi S (1993), Interindividual variations of desmethylation and hydroxylation of clomipramine in an oriental psychiatric population. J Clin Psychopharmacol 13:181-188
91. Skielbo E, Brosen K (1992), Inhibitors of imipramine metabolism by human liver microsomes. Br J Pharmacol 34:256-261
92. Song F, Freemantle N, Sheldon TA et al. (1993), Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptably. Br Med J 306:683-687
93. Spencer MJ (1993), Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics 92:721-722
94. Sperber AD (1991), Toxic interactions between fluvoxamine and sustained release theophylline in an 11-year old boy. Drug Saf 6:460-462
95. Steiner W, Fontaine R (1986), Toxic reaction following the combined administration of fluoxetine and 1-tryptophan: five case reports. Biol Psychiatry 21:1067-1071
96. Sternbach H (1991), The serotonin syndrome. Am J Psychiatry 148:705-713
97. Stokes PE (1993), Fluoxetine: a five year review. Clin Ther 15:210-243
98. Stoll AL, Cole JO, Lukas SE (1991), A case of mania as a result of fluoxetine-marijuana interaction. J Clin Psychiatry 52:280-281
99. Swims MP (1993), Potential terfenadine-fluoxetine interaction (letter). Ann Pharmacother 27:1404
100. Teicher MH, Glod C, Cole J (1990), Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 147:207-210
101. Tulloch IF, Johnson AM (1992), The pharmacologiec profile of paroxetine, a new selective serotonin reuptake inhibitor. J Clin Psychiatry 53(suppl):7-12
102. Venkataraman S, Naylor MW, King CA (1992), Mania associated with fluoxetine treatment in adolescents. J Am Acad Child Adolesc Psychiatry 31:276-281
103. von Moltke LL, Greenblatt DJ, Harmantz, JS, Shader RI (1994) Cytochromes in psychopharmacology. J Clin Pyschopharmacol 14:1-4
104. Walley T, Pirmohamed M, Proudlove C, Maxwell D (1993), Interaction of fluoxetine and metoprolol. Lancet 341:967-968
105. Walters AM (1992), Sympathomimetic-fluoxetine interaction (letter). J Am Acad Child Adolesc Psychiatry 31:565-566
106. Warrington SJ (1992), Clinical implications of the pharmacology of serotonin reuptake inhibitors. Int Clin Pychopharmacol 7:13-19
107. Wilens TE, Biederman J, Baldessarini RJ, Puopolo PR, Flood JG (1992) Developmental changes in serum concentrations of desipramine and 2-hydroxydesipramine during treatment with desipramine. J Am Acad Child Adolesc Psychiatry 31:691-698
108. Winokur A, Reynolds CF (1994), Effects of antidepressants on sleep physiology. Primary Psychiatry Nov/Dec, pp 22-27
109. Winokur A, Sewitch, Phillips JL, Biniaur IV (1991), Sleep architecture and mood effects of sertraline in outpatients with major depression: a preliminary report (abstract). Biol Psychiatry 29:43